miR-146b-5p enhances the sensitivity of NSCLC to EGFR tyrosine kinase inhibitors by regulating the IRAK1/NF-κB pathway
YN Liu, MF Tsai, SG Wu, TH Chang, TH Tsai… - … Therapy-Nucleic Acids, 2020 - cell.com
Although patients with non-small cell lung cancer harboring activating mutations in the
epidermal growth factor receptor (EGFR) show good clinical response to EGFR tyrosine …
epidermal growth factor receptor (EGFR) show good clinical response to EGFR tyrosine …
Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3
J Yue, D Lv, C Wang, L Li, Q Zhao, H Chen, L Xu - Oncogene, 2018 - nature.com
All lung cancers patients with epidermal growth factor receptor (EGFR) mutation inevitably
develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI). In up to 30% of cases …
develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI). In up to 30% of cases …
[HTML][HTML] Plasma microRNA alterations between EGFR-activating mutational NSCLC patients with and without primary resistance to TKI
Y Ma, X Pan, P Xu, Y Mi, W Wang, X Wu, Q He, X Liu… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have obtained
excellent therapeutic effects against non-small cell lung cancer (NSCLC) harboring …
excellent therapeutic effects against non-small cell lung cancer (NSCLC) harboring …
MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant …
HY Wang, YN Liu, SG Wu, CL Hsu… - Cancer …, 2020 - content.iospress.com
BACKGROUND: EGFR-mutant lung cancer inevitably develops resistance to epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). OBJECTIVE: To investigate …
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). OBJECTIVE: To investigate …
miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway
J Han, F Zhao, J Zhang, H Zhu… - International …, 2016 - spandidos-publications.com
Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs), such as gefitinib and erlotinib, is a critical issue for the treatment of EGFR mutant …
(TKIs), such as gefitinib and erlotinib, is a critical issue for the treatment of EGFR mutant …
miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124
Y Gao, XW Fan, WN Li, W Ping, Y Deng… - … and biophysical research …, 2014 - Elsevier
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) such as gefitinib are
clinically effective treatments for non-small cell lung cancer (NSCLC) patients with EGFR …
clinically effective treatments for non-small cell lung cancer (NSCLC) patients with EGFR …
Identification of microRNAs involved in gefitinib resistance of non‑small‑cell lung cancer through the insulin‑like growth factor receptor 1 signaling pathway
W Ma, Y Kang, L Ning, J Tan… - Experimental and …, 2017 - spandidos-publications.com
Multiple clinical and experimental studies have suggested that epidermal growth factor
receptor tyrosine kinase inhibitors (EGFR‑TKIs) may be effective at treating advanced non …
receptor tyrosine kinase inhibitors (EGFR‑TKIs) may be effective at treating advanced non …
[HTML][HTML] Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer
D Kaźmierczak, IJZ Eide, R Gencheva… - Translational Lung …, 2022 - ncbi.nlm.nih.gov
Background Non-small cell lung cancer (NSCLC) harboring activating mutations in the gene
encoding epidermal growth factor receptor (EGFR) is amenable for targeted therapy with …
encoding epidermal growth factor receptor (EGFR) is amenable for targeted therapy with …
[HTML][HTML] Long non-coding RNA LOC554202 promotes acquired gefitinib resistance in non-small cell lung cancer through upregulating miR-31 expression
J He, S Jin, W Zhang, D Wu, J Li, J Xu, W Gao - Journal of Cancer, 2019 - ncbi.nlm.nih.gov
Non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)
mutation inevitably have a relapse due to the occurrence of acquired resistance, resulting in …
mutation inevitably have a relapse due to the occurrence of acquired resistance, resulting in …
Downregulation of miR-506-3p facilitates EGFR-TKI resistance through induction of sonic hedgehog signaling in non-small-cell lung cancer cell lines
Non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)
mutation eventually develop resistance to EGFR-targeted tyrosine kinase inhibitors (TKIs) …
mutation eventually develop resistance to EGFR-targeted tyrosine kinase inhibitors (TKIs) …